Grail Encouraged By New Circulating Cell-free Genome Atlas Data
At the American Society of Clinical Oncology Annual Meeting on June 4, 2018, GRAIL announced the clinical results from a 127-patient sub-study of its Circulating Cell-free Genome Atlas (CCGA) trial. The analysis revealed that the company’s genome-sequencing blood tests can detect lung cancer with 98% specificity and up to 92% sensitivity. At that 98% specificity, the sensitivity of the tests ranged from 38% to 51% in participants with early-stage lung cancer, and from 87% to 89% in patients with later-stage cancer. “[The initial data from CCGA is...